In 2011, the world's four largest research consortia on the genetics of Alzheimer's disease joined efforts to discover and map the genes that contribute to Alzheimer's, forming the International Genomics of Alzheimer's Project (IGAP). The team collected genetic information from 25,500 Alzheimer's disease patients and 49,038 controls from 15 countries to perform this two-stage meta-analysis that resulted in the discovery of 11 new genes in addition to those already known, and the identification of 13 other genes, yet to be validated.
Margaret A. Pericak-Vance, Ph.D., the Dr. John T. Macdonald Foundation Professor of Human Genomics and Director of the John P. Hussman Institute for Human Genomics at the Miller School, and Lindsay A. Farrer, Ph.D., from Boston University, led the analysis teams for the American Alzheimer's Disease Genetics Consortium, which includes nearly all of the nation's researchers working on the genetics of Alzheimer's, as well as many investigators and resources of the 29 federally funded Alzheimer's Disease Centers.
Several of the genes the researchers identified confirmed known biological pathways of Alzheimer's disease, including the role of the amyloid (SORL1, CASS4) and tau (CASS4, FERMT2) pathways. Newly discovered genes involved in the immune response and inflammation (HLA-DRB5/DRB1, INPP5D, MEF2C) reinforced a pathway implied by previous work (on CR1, TREM2). Additional genes related to cell migration (PTK2B), lipid transport and endocytosis (SORL1) also were confirmed, and new hypotheses emerged related to hippocampal synaptic function (MEF2C, PTK2B), the cytoskeleton and axonal transport (CELF1, NME8, CASS4), as well as myeloid and microglial cell functions (INPP5D).
NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD. With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiantly.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!- Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative(